CAJ | 학술논문

目的：观察芪升合剂对接受NP化疗方案治疗非小细胞肺癌患者免疫能力的影响。方法：选择2005年3月至2013年9月来我院就诊的120例非小细胞肺癌患根据治疗方法不同分成两组，每组60人.两组均以NP化疗方案进行化疗，治疗组在每次化疗后口服150 mL芪升合剂，观察两组患者进行化疗前、后白细胞计数。比较两组患者免疫力情况及粒细胞集落刺激因子使用量及化疗后常见症状（易感冒、黏膜溃疡、头痛、呕吐、腹泻）积分。结果：两组患者的白细胞计数治疗后均低于治疗治疗前（P＜0.05），对照组的白细胞计数在治疗2、4、6个疗程时均高于对照组（P＜0.05）；治疗组患者的粒细胞集落刺激因子平均使用量低于对照组患者的使用量（P＜0.05）；治疗组症状积分低于对照组（P＜0.05）。结论：芪升合剂可有效改善应用NP化疗方案治疗非小细胞肺癌患者的免疫力，建议临床推广。
목적：관찰기승합제대접수NP화료방안치료비소세포폐암환자면역능력적영향。방법：선택2005년3월지2013년9월래아원취진적120례비소세포폐암환근거치료방법불동분성량조，매조60인.량조균이NP화료방안진행화료，치료조재매차화료후구복150 mL기승합제，관찰량조환자진행화료전、후백세포계수。비교량조환자면역력정황급립세포집락자격인자사용량급화료후상견증상（역감모、점막궤양、두통、구토、복사）적분。결과：량조환자적백세포계수치료후균저우치료치료전（P＜0.05），대조조적백세포계수재치료2、4、6개료정시균고우대조조（P＜0.05）；치료조환자적립세포집락자격인자평균사용량저우대조조환자적사용량（P＜0.05）；치료조증상적분저우대조조（P＜0.05）。결론：기승합제가유효개선응용NP화료방안치료비소세포폐암환자적면역력，건의림상추엄。
Objective:To observe the effect of Qisheng mixture on immunity of non-small cell lung cancer which accepted NP treatment . Methods:One hundred and twenty cases of non-small cell lung cancer patients admitted to our hospitals from March 2005 to September 2013 were divided into two groups according to the different treatment methods ,with 60 cases in each group .Both groups gave patients chemotherapy regimens NP ,and treatment group gave patients extra Qisheng mixture after each session of chemotherapy .White blood cell count,immunity circumstances and granulocyte colony-stimulating factor dosage were compared between the two groups before and after chemotherapy as well as the common symptoms scores after chemotherapy (colds,ulcers,headaches,vomiting,diarrhea) were observed. Results:The white blood cell count of two groups were both less than those before the treatment (P<0.05).At the second,fourth and sixth courses,the white blood cell count in the control group therapy were higher than the treatment group (P<0.05).The dosage of the G-CSF in the treatment was less than that of the control group (P<0.05).Treatment group symptom scores were lower than those of the control group ( P<0.05 ) .Conclusion:Qisheng mixture group can effectively improve the immunity of non-small cell lung cancer pa-tients who accepted NP treatment ,and it is recommended for clinical application .